KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Leases (2016 - 2025)

Historic Leases for Regeneron Pharmaceuticals (REGN) over the last 12 years, with Q4 2025 value amounting to $576.7 million.

  • Regeneron Pharmaceuticals' Leases fell 245.26% to $576.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $576.7 million, marking a year-over-year decrease of 245.26%. This contributed to the annual value of $576.7 million for FY2025, which is 245.26% down from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Leases of $576.7 million as of Q4 2025, which was down 245.26% from $591.2 million recorded in Q4 2024.
  • Over the past 5 years, Regeneron Pharmaceuticals' Leases peaked at $631.3 million during Q4 2021, and registered a low of $576.7 million during Q4 2025.
  • For the 5-year period, Regeneron Pharmaceuticals' Leases averaged around $605.0 million, with its median value being $605.7 million (2023).
  • Its Leases has fluctuated over the past 5 years, first crashed by 174.24% in 2022, then plummeted by 245.26% in 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' Leases (Quarter) stood at $631.3 million in 2021, then decreased by 1.74% to $620.3 million in 2022, then fell by 2.35% to $605.7 million in 2023, then dropped by 2.39% to $591.2 million in 2024, then decreased by 2.45% to $576.7 million in 2025.
  • Its last three reported values are $576.7 million in Q4 2025, $591.2 million for Q4 2024, and $605.7 million during Q4 2023.